A carregar...
Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
NTRK gene fusions affecting the tropomyosin receptor kinase (TRK) protein family have been found to be oncogenic drivers in a broad range of cancers. Small molecule inhibitors targeting TRK activity, such as the recently Food and Drug Administration-approved agent larotrectinib (Vitrakvi®), have sho...
Na minha lista:
| Publicado no: | Pathol Oncol Res |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Netherlands
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7297824/ https://ncbi.nlm.nih.gov/pubmed/31256325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12253-019-00685-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|